What is William Blair’s Estimate for AVIR FY2025 Earnings?

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) – William Blair cut their FY2025 earnings per share estimates for shares of Atea Pharmaceuticals in a research note issued to investors on Wednesday, November 12th. William Blair analyst A. Hsieh now expects that the company will post earnings of ($1.90) per share for the year, down from their previous forecast of ($1.72). The consensus estimate for Atea Pharmaceuticals’ current full-year earnings is ($2.01) per share. William Blair also issued estimates for Atea Pharmaceuticals’ Q4 2025 earnings at ($0.53) EPS, Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.90) EPS and FY2027 earnings at ($1.53) EPS.

Atea Pharmaceuticals (NASDAQ:AVIR) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.07).

Several other research firms have also weighed in on AVIR. Weiss Ratings restated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen downgraded Atea Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Atea Pharmaceuticals currently has an average rating of “Hold” and an average price target of $6.00.

Atea Pharmaceuticals Trading Up 2.0%

NASDAQ AVIR opened at $3.02 on Monday. The firm has a market capitalization of $235.95 million, a P/E ratio of -1.71 and a beta of 0.23. The firm’s fifty day moving average price is $3.11 and its two-hundred day moving average price is $3.25. Atea Pharmaceuticals has a 1 year low of $2.45 and a 1 year high of $4.02.

Hedge Funds Weigh In On Atea Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its stake in shares of Atea Pharmaceuticals by 9.2% during the third quarter. Dimensional Fund Advisors LP now owns 1,540,716 shares of the company’s stock worth $4,468,000 after purchasing an additional 129,453 shares during the period. CM Management LLC increased its position in Atea Pharmaceuticals by 66.7% during the 1st quarter. CM Management LLC now owns 500,000 shares of the company’s stock worth $1,495,000 after buying an additional 200,000 shares during the period. Millennium Management LLC lifted its holdings in shares of Atea Pharmaceuticals by 179.2% during the third quarter. Millennium Management LLC now owns 487,223 shares of the company’s stock worth $1,413,000 after buying an additional 312,733 shares in the last quarter. Two Sigma Investments LP lifted its holdings in shares of Atea Pharmaceuticals by 28.6% during the third quarter. Two Sigma Investments LP now owns 471,293 shares of the company’s stock worth $1,367,000 after buying an additional 104,681 shares in the last quarter. Finally, Peapod Lane Capital LLC boosted its position in shares of Atea Pharmaceuticals by 1.0% in the third quarter. Peapod Lane Capital LLC now owns 457,216 shares of the company’s stock valued at $1,326,000 after acquiring an additional 4,748 shares during the period. Institutional investors and hedge funds own 86.67% of the company’s stock.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.